Neuland Laboratories Reports Strong Q4 FY26 Financial Results
Hyderabad, India, May 12, 2026 - Neuland Laboratories Limited (NLL), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions services to customers in around 80 countries, announced its financial results for the year and quarter ended March 31, 2026.Commenting on the company's performance, Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, stated that the company ended FY26 on a strong note, aligning with original expectations. He noted that the business maintains good visibility in the short to medium term, anchored by commercial and near-commercial molecules. He emphasized that focusing on execution discipline, customer satisfaction, and protecting business fundamentals is central to ensuring sustained growth.
Davuluri also detailed the company's foundational strategy for future expansion. Key elements of this foundation include investments in Peptide Manufacturing and the new R&D Centre, both of which are proceeding according to plan. He added that the Business Development strategy is aligned with these investments and is focused on securing projects that support high-quality, sustainable growth.
Financial Performance Summary
The company reported significant increases across key financial metrics for Q4 FY26. The financial results compared to previous quarters and years are detailed below:| Rs. crore Particulars (Rs Cr) | Q4FY26 | Q4FY25 | YoY (%) | Q3FY26 | QoQ (%) |
|---|---|---|---|---|---|
| Total Income | 788.7 | 335.8 | 134.9% | 447.8 | 76.1% |
| EBITDA | 319.4 | 58.2 | 448.6% | 85.0 | 275.8% |
| EBITDA Margin | 40.5% | 17.3% | 2316 bps | 19.0% | 2151 bps |
| Profit Before Tax | 287.0 | 39.0 | 636.6% | 54.3 | 428.9% |
| PBT Margin | 36.4% | 11.6% | 2479 bps | 12.1% | 2430 bps |
| Profit After Tax | 212.5 | 27.7 | 666.3% | 40.4 | 425.8% |
For more information regarding Neuland Laboratories Limited, the company noted that it has been at the forefront of manufacturing APIs for over four decades. The organization has developed more than 300 processes and 100 APIs and holds numerous cGMP certifications, including U.S. FDA, TGA (Australia), and EMA (EU).
NEULANDLAB Stock Price Movement
Neuland Laboratories Limited shares today slipped by 2.56% to settle at ₹17,003. The stock experienced intraday trading between ₹16,905 and ₹17,753, moving on a volume of 106,204 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.